Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms - A meta-analysis

Urology

Volumn 83, Issue 3, 2014, Pages 556-562

  Hao, Nan ^a   Tian, Ye ^a   Liu, Wei ^a   Wazir, Romel ^a   Wang, Jianzhong ^a   Liu, Liangren ^a   Wang, Kunjie ^a   Li, Hong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE;

ARTICLE; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FLOW RATE; GENETIC HETEROGENEITY; HUMAN; LOWER URINARY TRACT SYMPTOM; META ANALYSIS; MICTURITION; MONOTHERAPY; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; SCORING SYSTEM; SYSTEMATIC REVIEW; URINARY URGENCY;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; URINATION; URODYNAMICS;

EID: 84896699710     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.10.034     Document Type: Article

References (30)

1. K.T. McVary BPH: epidemiology and comorbidities Am J Manag Care 12 2006 S122 S128
2. D.S.F. Calais, P. Marquis, and P. Deschaseaux et al. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study Eur Urol 31 1997 272 280
3. M. Oelke, A. Bachmann, and A. Descazeaud et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction Eur Urol 64 2013 118 140
4. B.B. Kortmann, D.L. Floratos, and L.A. Kiemeney et al. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials Urology 62 2003 1 9
5. K.E. Andersson, C.R. Chapple, and L. Cardozo et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence Curr Opin Urol 19 2009 380 394
6. A. Athanasopoulos, K. Gyftopoulos, and K. Giannitsas et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study J Urol 169 2003 2253 2256
7. K.S. Lee, M.S. Choo, and D.Y. Kim et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study J Urol 174 2005 1334 1338
8. O. Maruyama, Y. Kawachi, and K. Hanazawa et al. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study Int J Urol 13 2006 1280 1285
9. S.A. MacDiarmid, K.M. Peters, and A. Chen et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study Mayo Clin Proc 83 2008 1002 1010
10. T. Yokoyama, K. Uematsu, and T. Watanabe et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study Scand J Urol Nephrol 43 2009 307 314
11. N.K. Mohanty, A. Kumar, and M. Jain et al. Efficacy and safety of an alpha-blocker with and without anticholinergic agent in the management of lower urinary tract symptoms with detrusor overactivity Urotoday Int J 2 2009 10.3834/uij.1944-5784.2009.12.02
12. C. Chapple, S. Herschorn, and P. Abrams et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers Eur Urol 56 2009 534 541
13. Z.L. Wu, and H. Geng Combination of tolterodine and tamsulosin for benign prostatic hyperplasia Zhonghua Nan Ke Xue 15 2009 639 641
14. O. Yamaguchi, H. Kakizaki, and Y. Homma et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms-ASSIST, randomized controlled study Urology 78 2011 126 133
15. D.H. Seo, S.C. Kam, and J.S. Hyun Impact of lower urinary tract symptoms/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile function Korean J Urol 52 2011 49 54
16. S.H. Lee, B.H. Chung, and S.J. Kim et al. Initial combined treatment with anticholinergics and alpha-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study Prostate Cancer Prostatic Dis 14 2011 320 325
17. J.H. Bae, S.O. Kim, and E.S. Yoo et al. Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial Korean J Urol 52 2011 274 278
18. W. Gan, S.F. Zhang, and H.T. Jia et al. Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity Zhonghua Nan Ke Xue 17 2011 348 350
19. S.A. Kaplan, C.G. Roehrborn, and J. Gong et al. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms BJU Int 109 2012 1831 1840
20. P. Van Kerrebroeck, F. Haab, and J.C. Angulo et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN) Eur Urol 64 2013 398 407
21. Y. Yang, X.F. Zhao, and H.Z. Li et al. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study Chin Med J 120 2007 370 374
22. Y.M. Sun, W.D. Gu, and J.W. Lü et al. Combination of tamsulosin and tolterodine alleviates refractory lower urinary tract symptoms in male patients Zhonghua Nan Ke Xue 16 2010 790 793
23. T.J. Peters, J.L. Donovan, and H.E. Kay et al. The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms J Urol 157 1997 885 889
24. R. Dmochowski Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence? Curr Urol Rep 7 2006 462 467
25. S.A. Kaplan, K. McCammon, and R. Fincher et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency J Urol 189 2013 S129 S134
26. K.E. Andersson Antimuscarinics for treatment of overactive bladder Lancet Neurol 3 2004 46 53
27. K.E. Andersson Detrusor myocyte activity and afferent signaling Neurourol Urodyn 29 2010 97 106
28. S.A. Kaplan, and C.G. Roehrborn et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial JAMA 296 2006 2319 2328
29. P. Abrams, S. Kaplan, and G.H. De Koning et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction J Urol 175 2006 999 1004
30. R. Rackley, J.P. Weiss, and E.S. Rovner et al. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia Urology 67 2006 731 736